We are thrilled to share that we will be showcasing our high-throughput services at ELRIG Research & Innovation 2024 in Manchester! Join us at The University of Manchester to explore how our offerings can support your Drug Discovery journey. We…
Pelago Bioscience AB is a Discovery Research Partner serving the Drug Discovery community quantifying cellular target engagement of potential novel therapeutics from target validation to Candidate Drug nomination using our patented CETSA® technology platform. In connection with…
We’re delighted to share that our commitment to advancing Drug Discovery has earned us a spot in the “Top Ten Most Popular Drug Hunter Resources of 2023.” The insightful article, “Drug Target Identification Methods After a Phenotypic Screen,” published in…
We are thrilled to share that we will be showcasing our high-throughput services at SLAS2024 in Boston! Join us at the Boston Convention and Exhibition Center to explore how our offerings can support your Drug Discovery journey. We look forward…
We are thrilled to join the Drug Discovery Biology & Medicinal Chemistry Strategy Meetings hosted by Proventa International at Cambridge, MA at Le Meridien Hotel. We are excited to share our insights and experiences in the drug discovery field with…
The starting point for any desired biological effect is a drug-target interaction, an interaction that can be studied in a live cellular setting using the CETSA® technology. Drug hunters are now expanding the therapeutic target space to include harder to…
Learn how Pelago Bioscience and our technology CETSA®, Cellular Thermal Shift Assay can help you assess target engagement, and bring your projects forward with confidence through: • Physiologically relevant, robust data • Completely label-free • Transferability across matrices…
Protein degradation is a novel modality with the potential to tackle therapeutically interesting proteins previously seen as undruggable. In this area, CETSA® is a powerful technology for identifying binders, investigating target engagement and the mechanism of action of the protein…
In a recent collaboration between AbbVie Chemical Biology and Pelagoo Bioscience, CETSA® was applied to quantify direct target engagement of several inhibitors in unprocessed human whole blood. The study investigated RIPK1 as a proof-of-concept target, showcasing the high sensitivity and…
CETSA® by Pelago Bioscience is a well-proven, best-in-class technology used to assess cellular protein-compound binding in cell. CETSA® can be applied throughout all steps of the drug discovery value chain for screening, hit confirmation and selectivity. Because neither the ligand…